Philipp Geyer studied Molecular Biotechnology at the Technical University of Munich (TUM) and did his PhD thesis in Matthias Mann´s group at the Max Planck Institute of Biochemistry in Martinsried. The overall aim of his PhD was to pave the way for biomarker discovery and clinical applications of proteomics by precision characterization of the human blood plasma proteome. Here, he streamlined the previously time consuming and labor intensive proteomic workflow, resulting in a rapid, robust and highly reproducible robotic platform. After his PhD, Philipp Geyer continued his research in the Max Planck Institute of Biochemistry in Munich and the Center for Protein Research in Copenhagen, where he is heading the plasma proteomics efforts of the Matthias Mann´s group by supporting a team of several very dedicated students focusing on new technology developments and biomarker discovery. Highlights over the last years were the development of a high throughput MS-based plasma proteomics pipeline (Geyer et al., Cell Syst., 2016), the first proteomics study with more than 1000 plasma proteomes (Geyer et al., Mol Syst Biol, 2016), the idea of the “Rectangular” strategy for biomarker research (Geyer et al., Mol Syst Biol, 2017), publishing a systematic view of co-regulated protein networks in plasma (Albrechtsen & Geyer et al., Cell Syst., 2018) and the first biomarker panel with actionable candidates for non-alcoholic fatty liver disease (Niu & Geyer et al., Mol Syst Biol, 2019).